Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-102-12C
- Development stage
- Phase 1
- Lead developer
- Cells & Genes Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CG-102-12C is an autologous chimeric antigen receptor T cell (CAR-T) therapy under early-phase clinical investigation for the treatment of **advanced hepatocellular carcinoma (HCC)** that expresses glypican-3 (GPC3), a protein highly expressed on many liver cancer cells but largely absent from non-cancerous liver tissue. The drug consists of the patient’s own T cells genetically engineered to express a CAR targeting GPC3, allowing for **specific immune recognition and destruction of GPC3-positive tumor cells**. The trial explores safety, dose finding, persistence of CAR-T cells, and anti-tumor effect in patients who have failed standard therapies. CG-102-12C is developed by Cells & Genes Biotech (Shanghai) in collaboration with Zhejiang University, with research centers in China leading the first-in-human studies[1][2][6].
- Brand names
- CG-102-12CCG102-12CCG 102-12C
- Other names
- CG-102-12CCG102-12CCG 102-12C
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on CG-102-12C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-102-12C.